Diaceutics (DXRX) AI Stock Analysis

• Market Cap: £143.81M
• Dividend Yield: N/A
• Average Volume (3M): 79.63K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.50
• Revenue Growth: 31.83%
• EPS Growth: 46.59%
• Country: UK
• Employees: 184
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Diagnostics & Research
• EPS (TTM): -0.03
• Shares Outstanding: 84,912,440
• 10 Day Avg. Volume: 58,068
• 30 Day Avg. Volume: 79,634
• PEG Ratio: 25.77
• Price to Book (P/B): 2.66
• Price to Sales (P/S): 3.30
• P/FCF Ratio: -26.62
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: £215.00
• Price Target Upside: 33.13% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 57 Neutral
• Price Target: 176.00p ▲(8.98% Upside)

Diaceutics' strong revenue growth and positive corporate events are overshadowed by challenges in profitability, cash flow, and bearish technical indicators. The stock's valuation is also concerning due to negative earnings.

Positive Factors

Revenue Growth

Sustained double-digit revenue growth demonstrates successful product-market fit for Diaceutics’ precision-medicine analytics and services. Over 2–6 months this supports deeper customer engagement, enlarges addressable market, and enables scaling of platform and implementation offerings that can drive longer-term margin improvement.

Balance Sheet Strength

A conservative capital structure with very low leverage gives Diaceutics financial flexibility to fund multi-year contracts, invest in platform development, and weather revenue cyclicality without immediate refinancing risk. This stability supports durable operations and strategic investments over the medium term.

Specialized B2B Business Model

Niche positioning between pharma and diagnostics creates structural advantages: high switching costs, sticky client relationships, and potential for multi-year analytics contracts. The B2B subscription/project mix supports recurring revenues and long implementation cycles that favor sustained customer lifetime value and predictable demand.

Negative Factors

Profitability Pressure

Despite revenue growth, ongoing negative net and EBIT margins indicate operating costs outpacing sales, limiting the company's ability to turn top-line traction into sustainable profits. Over months this can constrain reinvestment, reduce free cashflow, and necessitate cost cuts or external financing to support growth initiatives.

Weakening Cash Generation

Deteriorating free cash flow erodes internal funding for platform maintenance, customer implementation work, and R&D. Over a 2–6 month horizon this raises liquidity risk, increases reliance on financing or equity issuance, and may force prioritization of short-term cash conservation over long-term strategic projects.

Declining Stockholders' Equity Trend

An erosion in shareholders' equity, even with a currently high equity ratio, signals cumulative losses or capital outflows that reduce the balance-sheet buffer. This weakens the company’s shock absorption capacity and may limit future borrowing or investment flexibility, pressuring growth plans and strategic spending.

Diaceutics Business Overview & Revenue Model

Company Description

Diaceutics (DXRX) is a data analytics and technology company specializing in precision medicine and diagnostics. The company operates primarily in the healthcare sector, providing solutions that enhance the development and commercialization of targeted therapies. Diaceutics offers a comprehensive platform that integrates diagnostic data, patient insights, and real-world evidence, enabling pharmaceutical companies to optimize their strategies in personalized medicine, improve patient outcomes, and streamline the diagnostic journey.

How the Company Makes Money

Diaceutics generates revenue through a combination of subscription fees, consulting services, and data analytics solutions. The company offers a subscription-based model for its DXRX platform, where pharmaceutical companies pay for access to advanced analytics and insights that help them navigate the complexities of precision medicine. Additionally, Diaceutics provides consulting services that assist clients in understanding market dynamics and developing strategies for effective product launches. Key revenue streams include partnerships with pharmaceutical companies, which often involve long-term contracts for data services and analytics tools. The company also benefits from collaborations with diagnostic laboratories and healthcare organizations, enhancing its ability to provide comprehensive solutions and expanding its customer base.

Diaceutics Financial Statement Overview

Summary

Diaceutics shows strong revenue growth but struggles with profitability and cash flow management. The balance sheet is robust with high equity and low leverage, providing financial stability.

Income Statement

Diaceutics has shown significant revenue growth from the previous year, with a revenue increase of 35.71% in 2024 compared to 2023. However, the company is struggling with profitability, as indicated by negative net profit margins and EBIT margins, which suggest high operational costs relative to revenue. Despite a positive EBITDA margin, the overall profitability is challenged by persistent losses.

Balance Sheet

The company's balance sheet is relatively strong with a high equity ratio of 82.00%, indicating a stable financial foundation and minimal reliance on debt, as shown by a low debt-to-equity ratio of 0.03. However, the declining trend in stockholders' equity over the years raises concerns about the sustainability of this stability.

Cash Flow

Diaceutics has experienced a decline in free cash flow, moving from a positive value in 2022 to negative in 2024, highlighting challenges in operational cash generation. The operating cash flow to net income ratio suggests issues in converting income to cash, which could impact liquidity. Despite these challenges, the company maintains a cautious approach to financing activities.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	34.40M	32.16M	23.70M	19.50M	13.94M	12.70M
Gross Profit	29.63M	28.27M	19.71M	14.04M	10.57M	9.33M
EBITDA	2.69M	2.77M	2.36M	3.61M	2.35M	178.00K
Net Income	-1.52M	-1.70M	-1.75M	724.00K	561.00K	263.00K
Balance Sheet
Total Assets	44.42M	48.62M	46.34M	48.26M	45.01M	43.52M
Cash, Cash Equivalents and Short-Term Investments	10.38M	12.74M	16.67M	19.84M	19.68M	25.25M
Total Debt	1.13M	1.06M	1.21M	1.33M	1.56M	118.00K
Total Liabilities	7.18M	8.76M	5.56M	5.74M	4.36M	3.28M
Stockholders Equity	37.24M	39.86M	40.79M	42.51M	40.65M	40.24M
Cash Flow
Free Cash Flow	10.00K	-3.98M	-3.54M	278.00K	-5.03M	-6.04M
Operating Cash Flow	104.00K	651.00K	1.31M	5.15M	570.00K	253.00K
Investing Cash Flow	-5.76M	-4.03M	-4.21M	-4.87M	-5.60M	-6.29M
Financing Cash Flow	-242.00K	-64.00K	-239.00K	-132.00K	-270.00K	19.61M

Diaceutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 161.50
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:DXRX, the sentiment is Positive. The current price of 161.5 is above the 20-day moving average (MA) of 154.97, above the 50-day MA of 146.69, and above the 200-day MA of 140.74, indicating a bullish trend. The MACD of 7.61 indicates Negative momentum. The RSI at 71.59 is Negative, neither overbought nor oversold. The STOCH value of 51.98 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GB:DXRX.

Diaceutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
EKF	67 Neutral	£106.30M	18.22	8.71%	―	-1.43%	28.57%
DXRX	57 Neutral	£143.81M	-94.44	-3.95%	―	31.83%	46.59%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
CLBX	48 Neutral	£13.64M	-0.25	-87.18%	―	29.64%	28.51%
GDR	47 Neutral	£11.07M	-1.16	-153.92%	―	90.42%	79.21%
RENX	43 Neutral	£25.13M	-0.40	425.97%	―	-4.48%	61.09%
OBD	38 Underperform	£11.80M	-0.29	-407.49%	―	72.17%	79.03%

Diaceutics Corporate Events

Diaceutics Returns to Profit as Recurring Revenues and Order Book Hit Record Highs

Diaceutics reported an estimated 20% rise in 2025 revenues to £38.5 million, a return to profitability and a roughly 75% jump in adjusted EBITDA, underpinned by strong demand for its precision medicine commercialisation platform and greater adoption across 95 therapeutic brands. Annual recurring revenue grew 21% to more than £20.3 million and the order book expanded 48% to at least £36.8 million, reflecting increased multi-year enterprise engagements, including a second PMx commercialisation partnership with a US biotech; with AI-driven efficiency gains and a robust pipeline, the company forecasts 25% revenue growth in 2026, reinforcing its position as a key enabler of the pharma industry’s shift toward precision medicine.

The most recent analyst rating on (GB:DXRX) stock is a Hold with a £142.00 price target. To see the full list of analyst forecasts on Diaceutics stock, see the GB:DXRX Stock Forecast page.

Diaceutics Issues Shares to Trust Under Ongoing Incentive Plan, Updates Total Voting Rights

Diaceutics has reported that the trustees of its Global 2020 Employee Benefit Trust have been purchasing ordinary shares on behalf of several senior managers under the company’s UK and Global Share Incentive Plan, with these purchases set to continue monthly until further notice. In line with the plan’s terms, Diaceutics has matched employee purchases on a 1:1 basis, issuing 6,486 new shares to its UK trust to satisfy matched awards, bringing the total number of shares in issue to 84,912,435 and providing an updated reference figure for investors monitoring their holdings under UK disclosure rules.

The most recent analyst rating on (GB:DXRX) stock is a Hold with a £142.00 price target. To see the full list of analyst forecasts on Diaceutics stock, see the GB:DXRX Stock Forecast page.

Diaceutics PLC Expands Employee Share Incentive Plan

Diaceutics PLC has announced that trustees of its 2020 Employee Benefit Trust have purchased ordinary shares on behalf of certain key personnel as part of the company’s UK and Global Share Incentive Plan. These purchases, matched by the company with an equivalent number of shares, are part of an ongoing scheme to incentivize employees, reflecting Diaceutics’ commitment to aligning employee interests with company performance. The company has issued 5,221 shares to the UK Trust to settle these matched share awards, contributing to the total of 84,905,949 shares in issue, which shareholders can use to determine their interest in the company under regulatory guidelines.

The most recent analyst rating on (GB:DXRX) stock is a Hold with a £171.00 price target. To see the full list of analyst forecasts on Diaceutics stock, see the GB:DXRX Stock Forecast page.

Diaceutics PLC Enhances Employee Engagement with Share Incentive Plan

Diaceutics PLC has announced that its trustees have purchased ordinary shares on behalf of key personnel as part of the company’s Share Incentive Plan (SIP) for employees. This initiative, which involves matching employee share purchases with a 1:1 share award, aims to facilitate employee participation in the company’s growth and aligns with their strategic goals to enhance stakeholder engagement and transparency.

The most recent analyst rating on (GB:DXRX) stock is a Hold with a £171.00 price target. To see the full list of analyst forecasts on Diaceutics stock, see the GB:DXRX Stock Forecast page.